HPV Testing & Cervical Cancer Screening: A Complete Guide to Molecular Diagnostics

High-risk HPV genotyping, DNA and mRNA testing strategies, ASC-US triage protocols, and specimen options — a comprehensive resource for clinical laboratories and IVD professionals.

Cervical cancer remains one of the most common malignant tumors in women, ranking fourth in incidence among female cancers globally. Extensive clinical studies have demonstrated that human papillomavirus (HPV) infection is the primary causative etiological factor of cervical cancer. In particular, persistent infection with high-risk HPV types, such as HPV 16 and HPV 18, is closely associated with oncogenesis and the development of cervical malignancies.

Approximately 99% of cervical cancer cases present detectable high-risk HPV infections, proving that HPV infection is a necessary prerequisite condition for the development of cervical cancer. Although the majority of transient HPV infections can be cleared spontaneously by the host immune system within 1 to 2 years, persistent high-risk HPV infection can lead to abnormal epithelial cell proliferation in the cervix, gradually progressing into precancerous lesions and invasive cervical cancer.

The progression of cervical cancer is typically a slow, multi-stage evolutionary process, moving from normal cervical epithelial cells to precancerous lesions—such as cervical intraepithelial neoplasia (CIN)—and ultimately into invasive carcinoma. This progression can span several years or even decades. Crucially, the therapeutic outcome of cervical cancer is closely correlated with tumor staging. Clinical treatment outcomes are significantly more favorable for early-stage cervical diseases (such as CIN1 and CIN2), whereas the efficacy decreases substantially for patients diagnosed in intermediate and late stages. Therefore, early diagnosis via robust molecular screening is vital for the prevention and treatment of cervical cancer.

01 Screening Methods for Cervical Cancer

Multiple diagnostic screening methods are currently deployed in clinical practice to detect cervical abnormalities:

• Cytological Testing (TCT / ThinPrep Cytologic Test): By collecting exfoliated cervical cell samples and utilizing microscopic observation to examine cellular morphological changes, this liquid-based cytology method screens for precancerous lesions or malignant cells. While TCT is a traditional, widely accepted screening method, its clinical sensitivity can be limited by sample collection quality and the subjective experience of laboratory technical personnel.
• Colposcopy: If cytological test results indicate abnormalities, physicians usually recommend a colposcopy. This diagnostic procedure allows for the magnified visual observation of lesions on the cervical surface via a colposcope, enabling targeted biopsies to establish a definitive diagnosis. Histopathological examination of biopsy tissue remains the gold standard for diagnosing cervical cancer.
• HPV Molecular Testing: This advanced molecular assay detects the viral genome of HPV within cervical cells, with a specific focus on high-risk oncogenic genotypes. Compared to traditional cytological testing, HPV molecular testing offers significantly higher sensitivity, enabling clinical teams to identify high-risk patient populations at an earlier stage.

02 Classification of HPV Genotypes

Human papillomaviruses are strictly classified into low-risk and high-risk types based on their specific oncogenic potential:

• Low-Risk HPV: Genotypes such as HPV 6 and HPV 11 primarily cause benign epithelial lesions, such as condyloma acuminata (genital warts), and typically do not induce malignant transformation or carcinogenesis.
• High-Risk HPV: Genotypes including HPV 16 and HPV 18 are closely linked to cervical carcinogenesis, accounting for approximately 70% of all documented cervical cancer cases. Other recognized high-risk types include HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68, which can likewise contribute to cervical precancerous lesions and other reproductive tract malignancies.

03 HPV Molecular Testing Strategies and Sample Types

Modern IVD molecular diagnostic strategies for HPV include several distinct methodologies:

• HPV DNA Testing: Currently the most widely adopted molecular assay in clinical laboratories, it utilizes polymerase chain reaction (PCR) technology to detect specific HPV DNA target sequences, delivering high analytical sensitivity.
• HPV mRNA Testing: This assay measures the transcription and mRNA expression levels of the oncogenic HPV E6/E7 genes. It features higher diagnostic specificity, making it an ideal tool for further clinical triage, secondary screening, and diagnostic confirmation.
• HPV Integration Testing: By detecting whether the viral genome has integrated into the host cell genome, this method evaluates the advanced oncogenic potential of the infection.
• Gene Methylation Testing: During the process of cervical epithelial cell carcinogenesis induced by persistent HPV infection, specific epigenetic methylation changes occur in both the viral DNA and host genomic DNA. By detecting these gene methylation biomarkers, clinicians can assess the immediate risk of advanced precancerous lesions or early-stage cervical cancer, greatly improving screening accuracy.

The diversification of validated sample types has made molecular testing more accessible and entirely non-invasive. Common sample matrices include:

• Cervical Exfoliated Cell Samples: The standard and most frequently utilized sample type, delivering excellent diagnostic sensitivity and clinical specificity.
• Vaginal Exfoliated Cell Samples: Highly suitable for individuals who cannot easily undergo speculum-based cervical sampling; vaginal self-sampling is simple, private, and convenient to operate.
• Urine Samples: A completely non-invasive detection matrix, ideal for home-based screening or women for whom traditional clinical cervical sampling is inconvenient.

04 Primary Clinical Application Pathways of HPV Molecular Testing

In contemporary clinical workflows, HPV molecular testing reagents are deployed primarily through three distinct pathways:

• Primary Screening for Cervical Cancer and Precancerous Lesions: Utilized as a standalone or co-testing frontline assay to detect high-risk HPV types (such as HPV 16 and HPV 18). Combined with cervical cytology, it facilitates the early detection of cervical precancerous lesions or early carcinogenic risks.
• Auxiliary Diagnosis of Cervical Lesions: For patients presenting abnormal cytological findings or suspicious clinical lesions, determining high-risk HPV infection status assists in differentiating benign from malignant pathology, directly supporting disease staging and clinical management decisions.
• Triage of the ASC-US Population: Deployed as a reflex test when a Pap smear report indicates Atypical Squamous Cells of Undetermined Significance (ASC-US). The high-risk HPV assay status acts as the key triage mechanism to decide whether the patient should be referred for colposcopy.

05 Intended Target Populations for HPV Molecular Testing

• Sexually Active Women: Because cervical cancer is fundamentally driven by high-risk HPV transmission, sexually active women experience a baseline risk of acquisition. It is strongly recommended that women aged 30 and older undergo routine, regular HPV molecular testing, as persistent infections are more prevalent in this demographic and precancerous lesions are more likely to emerge.
• Individuals with Abnormal Primary Screening Results: Women who present abnormal or equivocal cytological tests (TCT) are advised to undergo adjunctive HPV molecular testing to optimize diagnostic accuracy.
• High-Risk Immunocompromised Populations: Individuals under immunosuppressive therapy or those living with HIV are highly vulnerable to persistent HPV infections and accelerated lesion progression, necessitating stringent monitoring.
• Women with a Family History of Cervical Cancer: Individuals with first-degree relatives diagnosed with cervical cancer or advanced precancerous lesions carry an elevated risk profile, making routine molecular monitoring highly recommended.